Praxis Relutrigine FDA Decision Pushed to Dec. 27 on Major Amendment

The FDA extended its review of Praxis Precision Medicines' relutrigine by three months, pushing the target action date to Dec. 27 from the original Sept. 27 deadline. The agency cited a "major amendment" to the new drug application, a classification that typically resets the review clock to a full three-month cycle.

Relutrigine targets developmental and epileptic encephalopathies caused by mutations in the SCN2A and SCN8A genes. These are rare, severe pediatric seizure disorders with no approved therapies addressing the underlying sodium-channel dysfunction. The FDA has granted the drug orphan drug and rare pediatric disease designations, which qualify for priority review vouchers and extended market exclusivity upon approval.

Praxis did not specify what the amendment contained. Major amendments can include new clinical data, manufacturing changes, or updated safety analyses submitted after the initial filing. The FDA accepted the amendment for review, meaning it considers the material substantive enough to warrant a full evaluation cycle.

The delay shifts any potential launch into 2026, assuming a December approval. Praxis had previously guided for a possible launch in the first half of 2026. A December PDUFA date pushes that timeline to mid-2026 at the earliest, given the typical lead time for manufacturing, labeling, and commercial preparation.

Praxis is a clinical-stage company with no approved products. The extension adds roughly six months of cash burn before any relutrigine revenue arrives. The company said its current cash position provides runway into the second half of 2026, a timeline the delay does not breach, though it narrows the margin.

The SCN2A and SCN8A populations are small, estimated at a few thousand patients in the U.S. combined. Current treatment relies on broad-spectrum antiseizure drugs that often fail or carry intolerable side effects. Relutrigine, if approved, would be the first precision therapy for these mutations.

The FDA has not scheduled an advisory committee meeting for relutrigine. Praxis has noted that absence as a positive signal, since the agency typically convenes panels for drugs with novel mechanisms or borderline efficacy data. The lack of a panel suggests the review is proceeding on standard track.

Praxis plans to discuss the regulatory path during its next earnings call, scheduled for early November. The Dec. 27 PDUFA date is a statutory deadline, and the FDA could act earlier if the review completes ahead of schedule.